Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
35 hedge funds and large institutions have $14.7M invested in Cellular Biomedicine Group, Inc. in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 4 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
375% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 4
17% more funds holding
Funds holding: 30 → 35 (+5)
22% less capital invested
Capital invested by funds: $18.9M → $14.7M (-$4.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$963K |
| 2 |
Goldman Sachs
New York
|
+$300K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$274K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$231K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$161K |
| 2 |
Citigroup
New York
|
-$110K |
| 3 |
State Street
Boston,
Massachusetts
|
-$35.8K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$15.2K |
| 5 |
Morgan Stanley
New York
|
-$739 |
CBMG Hedge Fund Activity: Q2 2016 in Review
35 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q2 2016, worth a combined $14.7M — down 22% from $18.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CBMG positions and 1 closed out — a net gain of 5 holders — while 19 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $963K. The largest seller was Metropolitan Life Insurance Company (MetLife), exiting entirely with an estimated $161K sold.
- 35 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q2 2016, up from 30 in Q1 2016.
- Funds reported $14.7M of Cellular Biomedicine Group, Inc. stock for Q2 2016, down 22% quarter-over-quarter.
- 6 funds opened new Cellular Biomedicine Group, Inc. positions in Q2 2016 and 1 closed out, a net change of +5 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $963K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q2 2016 was Metropolitan Life Insurance Company (MetLife), an estimated $161K sold.
Based on aggregated 13F filings for Q2 2016.